Adverse event (AE) reporting is a crucial part of patient safety protection in the clinical research world. The FDA and other regulators require that clinical trial sponsors file reports on AEs, both to regulators and back to research sites. But in recent years, both the FDA and research sites have struggled under a veritable flood of AE reports that principal investigators must review to determine causality.